For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Despite the diverse nature of obesity, there is compelling genetic, clinical, and experimental evidence that endorses the ...

According to the WHO, over 64 million adults and 300,000 children and adolescents in Europe are currently living with ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...

This intrusive, but common phenomenon can take over your life, affecting your state of mind and eating habits. Weight-loss drugs show promise in quieting these thoughts.

These drugs imitate the actions of GLP-1. They target the appetite control centre in the hypothalamus area of the brain to reduce hunger pangs; slow down the rate the food leaves the stomach, leaving ...